Hu Minqi, Chua Song Lin
Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
Microorganisms. 2025 Apr 16;13(4):913. doi: 10.3390/microorganisms13040913.
Antibiotic-resistant is a pathogen notorious for its resilience in clinical settings due to biofilm formation, efflux pumps, and the rapid acquisition of resistance genes. With traditional antibiotic therapy rendered ineffective against infections, we explore alternative therapies that have shown promise, including antimicrobial peptides, nanoparticles and quorum sensing inhibitors. While these approaches offer potential, they each face challenges, such as specificity, stability, and delivery, which require careful consideration and further study. We also delve into emerging alternative strategies, such as bacteriophage therapy and CRISPR-Cas gene editing that could enhance targeted treatment for personalized medicine. As most of them are currently in experimental stages, we highlight the need for clinical trials and additional research to confirm their feasibility. Hence, we offer insights into new therapeutic avenues that could help address the pressing issue of antibiotic-resistant , with an eye toward practical applications in future healthcare.
抗生素耐药性是一种病原体,因其在临床环境中通过形成生物膜、外排泵以及快速获得耐药基因而具有很强的恢复力而声名狼藉。由于传统抗生素疗法对[病原体名称]感染无效,我们探索了已显示出前景的替代疗法,包括抗菌肽、纳米颗粒和群体感应抑制剂。虽然这些方法具有潜力,但它们各自都面临挑战,如特异性、稳定性和递送问题,这需要仔细考虑和进一步研究。我们还深入研究了新兴的替代策略,如噬菌体疗法和CRISPR-Cas基因编辑,这些策略可以增强个性化医学的靶向治疗。由于它们中的大多数目前正处于实验阶段,我们强调需要进行临床试验和更多研究以确认其可行性。因此,我们提供了关于新治疗途径的见解,这些途径有助于解决抗生素耐药性这一紧迫问题,并着眼于在未来医疗保健中的实际应用。 (注:原文中“Antibiotic-resistant”后应补充完整的病原体名称等相关信息,这里按现有内容翻译)